The lawsuits filed by people affected by GLP-1 medications focus on several serious gastrointestinal injuries: Gastroparesis (stomach paralysis) , a condition where the stomach loses its ability to properly move food into the small intestine, causing severe nausea, vomiting, malnutrition, and requiring long-term dietary changes or feeding tubes Ileus , a temporary but serious condition where intestinal motility stops, causing severe pain, bloating, inability to pass gas or stool, and sometimes requiring hospitalization Intestinal obstruction , including mechanical blockages and pseudo-obstruction where the intestines stop functioning without a physical blockage Severe and persistent nausea and vomiting , often requiring emergency room visits, IV fluids, and anti-nausea medications Cyclic vomiting syndrome , characterized by repeated episodes of severe vomiting with no apparent cause Malnutrition and severe weight loss , resulting from the inability to eat or digest food properly Dehydration and electrolyte imbalances , caused by persistent vomiting and inability to keep fluids down Many of these conditions have required hospitalization, feeding tubes, surgical interventions, and permanent dietary restrictions
Adult Myopathic CPT-2 Deficiency The adult form of CPT2 deficiency, the myopathic form, is the most common form of CPT2 deficiency
The dosage gradually increases until it reaches the weight-loss dose of 2.4mg per week
That's a clear benefit when it comes to outsmarting diabetes
For reference, the 232 participants in the semaglutide arm achieved an average body weight loss of 17.3%, and the 101 participants in the placebo arm achieved an average body weight loss of 2.0%
Fiber not only combats gastroparesis-related constipation but also supports the gut health that's crucial during medication adjustment periods
